<SEC-DOCUMENT>0001477932-17-002726.txt : 20170608
<SEC-HEADER>0001477932-17-002726.hdr.sgml : 20170608
<ACCEPTANCE-DATETIME>20170608170025
ACCESSION NUMBER:		0001477932-17-002726
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170607
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170608
DATE AS OF CHANGE:		20170608

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001506251
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273425913
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55532
		FILM NUMBER:		17900775

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6676

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trail One, Inc.
		DATE OF NAME CHANGE:	20110314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrailOne, Inc.
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ctxr_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>

<html><head><title>ctxr_8k.htm</title><!--Document Created by EDGARMaster--></head><BODY style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="center">
<table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td>
<div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div>
<div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><font size="3"><b>UNITED STATES</b></font></p>
<p style="MARGIN: 0px" align="center"><font size="3"><b>SECURITIES AND EXCHANGE COMMISSION</b></font></p>
<p style="MARGIN: 0px" align="center"><font size="3"><b>Washington, D.C. 20549</b></font></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><font size="5">FORM 8-K</font></b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">CURRENT REPORT</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">Date of Report (Date of earliest event reported) <b>June 7, 2017</b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="50%" align="center" border="0">

<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center"><b><font size="5">Citius Pharmaceuticals, Inc.</font></b></p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center">(Exact name of registrant as specified in its charter)</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="5" cellpadding="0" width="85%" align="center" border="0">

<tr>
<td style="BORDER-BOTTOM: black 1px solid" width="30%">
<p style="MARGIN: 0px" align="center"><b>Nevada</b></p></td>
<td width="5%">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" width="30%">
<p style="MARGIN: 0px" align="center"><b>333-206903 </b></p></td>
<td width="5%">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" width="30%">
<p style="MARGIN: 0px" align="center"><b>27-3425913 </b></p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center">(State or other jurisdiction </p>
<p style="MARGIN: 0px" align="center">of incorporation)</p></td>
<td>
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">(Commission<br>File Number)</p></td>
<td>
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">(IRS Employer<br>Identification No.)</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="3" cellpadding="0" width="85%" align="center" border="0">

<tr>
<td style="BORDER-BOTTOM: black 1px solid" width="45%">
<p style="MARGIN: 0px" align="center"><b>11 Commerce Drive, 1st Floor </b></p>
<p style="MARGIN: 0px" align="center"><b>Cranford, NJ</b></p></td>
<td width="10%">
<p style="MARGIN: 0px" align="center"><b>&nbsp;</b></p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="45%">
<p style="MARGIN: 0px" align="center"><b>07016</b></p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center">(Address of principal executive offices)</p></td>
<td>
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="center">(Zip Code)</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">Registrant's telephone number, including area code <u><b>(908) 967-6677 </b></u></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Wingdings">&#168; </font>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Wingdings">&#168; </font>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Wingdings">&#168; </font>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Wingdings">&#168; </font>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td>
<div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div>
<div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p>
<p style="MARGIN: 0px">
<table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On June 7, 2017, Citius Pharmaceuticals, Inc. (the &#8220;Company&#8221;) filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada (the &#8220;Amendment&#8221;) to effectuate a reverse stock split (the &#8220;Reverse Stock Split&#8221;) of its issued and outstanding shares of common stock on a 1-for-15 basis. The Reverse Stock Split becomes effective on June 9, 2017 (the &#8220;Effective Date&#8221;). As of the Effective Date, every 15 shares of issued and outstanding common stock will be converted into one share of common stock. No fractional shares will be issued in connection with the Reverse Stock Split. Instead, a holder of record of common stock on the Effective Date who would otherwise be entitled to a fraction of a share will, in lieu thereof, be entitled to receive a whole share of common stock.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">All options, warrants and convertible securities of the Company outstanding immediately prior to the Reverse Stock Split will be proportionately adjusted for the Reverse Stock Split by dividing the number of shares of common stock into which the options, warrants and convertible securities are exercisable or convertible by 15 and multiplying the exercise or conversion price thereof by 15.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As reported on the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 15, 2016, the Company&#8217;s shareholders authorized the Company&#8217;s Board of Directors to effect a reverse stock split of the Company&#8217;s common stock in a ratio in the range of not less than 1-for-8 and not more than 1-for-20 at any time prior to September 15, 2017. Thereafter, the Company&#8217;s Board of Directors determined to effect the Reverse Stock Split and authorized the implementation of the Reverse Stock Split and filing of the Amendment. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The forgoing description is a summary only, does not purport to set forth the complete terms of the Amendment, and is qualified in its entirety by reference to the Amendment filed as Exhibit 3.1 to this Current Report on Form 8-K.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">On June 8, 2017, we issued a press release with respect to the Reverse Stock Split described above, a copy of which is being filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Item 9.01. Financial Statements and Exhibits</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">(d) <i>Exhibits.</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr height="15">
<td style="BORDER-BOTTOM: black 1px solid" valign="top" width="9%">
<p style="MARGIN: 0px" align="left"><b>Exhibit No.</b></p></td>
<td width="2%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="left"><b>Description of Exhibit</b></p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href="ctxr_ex31.htm">3.1</a></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href="ctxr_ex31.htm">Certificate of Amendment of the Amended and Restated&nbsp;Articles of Incorporation of Citius Pharmaceuticals, Inc. effective June 9, 2017.</a></p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href="ctxr_ex991.htm">99.1</a></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href="ctxr_ex991.htm">Press Release dated June 8, 2017.</a></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak4a395849-78d9-43b7-826a-1dfe2525e05e" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">2</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>SIGNATURE</b><b><u></u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td>&nbsp;</td>
<td colspan="2">
<p style="MARGIN: 0px"><b>CITIUS PHARMACEUTICALS, INC.</b></p></td>
<td></td></tr>
<tr>
<td width="50%">&nbsp;</td>
<td width="3%">&nbsp;</td>
<td width="35%">&nbsp;</td>
<td width="12%">&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">Date: June 8, 2017 </p></td>
<td>By:</td>
<td style="BORDER-BOTTOM: black 1px solid"><em>/s/ Myron Holubiak </em></td>
<td></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">Myron Holubiak </p></td>
<td>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>
<p style="MARGIN: 0px">President and Chief Executive Officer </p></td>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0">

<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center">&nbsp;3</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p></BODY></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ctxr_ex31.htm
<DESCRIPTION>CERTIFICATE OF AMENDMENT
<TEXT>

<html><head><title>ctxr_ex31.htm</title><!--Document Created by EDGARMaster--></head><BODY style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 3.1</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>CERTIFICATE OF AMENDMENT TO ARTICLES OF INCORPORATION </b><b>OF</b></p>
<p style="MARGIN: 0px" align="center"><b>CITIUS PHARMACEUTICALS, INC.</b></p>
<p style="MARGIN: 0px" align="center"><b>(Pursuant to NRS 78.385 and 78.390 &#8211; After Issuance of Stock</b>)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">Pursuant to NRS 78.385 and 78.390 of the Nevada Revised Statutes, the undersigned corporation hereby submits this Certificate of Amendment to Articles of Incorporation for the purpose of amending its Articles of Incorporation.&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">1.</td>
<td valign="top">The name of the corporation is Citius Pharmaceuticals, Inc. (the &#8220;Corporation&#8221;).</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">2.</td>
<td valign="top">The following amendment to the Corporation&#8217;s Articles of Incorporation was adopted by the board of directors of the Corporation and by majority consent of the stockholders of the Corporation in the manner prescribed by applicable law.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"></td>
<td valign="top">Article FOURTH is hereby amended by inserting the following at the end of such Article:</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"></td>
<td valign="top">&#8220;Effective immediately upon the filing of this Certificate of Amendment to Articles of Incorporation with the Secretary of State of the State of Nevada (the &#8220;Effective Time&#8221;), the shares of Common Stock and Preferred Stock issued and outstanding immediately prior to the Effective Time and the shares of Common Stock and Preferred Stock issued and held in the treasury of the Corporation immediately prior to the Effective Time are reclassified into a larger number of shares such that each fifteen (15) shares of issued Common Stock immediately prior to the Effective Time is reclassified into one (1) share of Common Stock and each fifteen (15) shares of issued Preferred Stock immediately prior to the Effective Time is reclassified into one (1) share of Preferred Stock. Notwithstanding the immediately preceding sentence, no fractional shares shall be issued and, in lieu thereof, upon surrender after the Effective Time of a certificate which formerly represented shares of Common Stock or Preferred Stock that were issued and outstanding immediately prior to the Effective Time, any person who would otherwise be entitled to a fractional share of Common Stock or Preferred Stock, as appropriate, as a result of the reclassification, following the Effective Time, shall be entitled to receive a whole share in lieu of the fraction to which such holder would otherwise be entitled, immediately following the Effective Time.</td></tr></tr></tr></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak8a1325b6-eb87-4a2b-a043-7badd4253832" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">1</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"></td>
<td valign="top">Each stock certificate that, immediately prior to the Effective Time, represented shares of Common Stock or Preferred Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock or Preferred Stock, as appropriate, after the Effective Time into which the shares of Common Stock or Preferred Stock, as appropriate, formerly represented by such certificate shall have been reclassified (as well as the right to receive a whole share in lieu of fractional shares of Common Stock or Preferred Stock after the Effective Time), provided, however, that each person of record holding a certificate that represented shares of Common Stock or Preferred Stock that were issued and outstanding immediately prior to the Effective Time shall receive, upon surrender of such certificate, either a new certificate evidencing and representing the number of whole shares of Common Stock or Preferred Stock, as appropriate, after the Effective Time into which the shares of Common Stock or Preferred Stock, as appropriate, formerly represented by such certificate shall have been reclassified or evidence that the Corporation&#8217;s transfer agent has registered in electronic or &#8220;book entry&#8221; format the number of whole shares of Common Stock or Preferred Stock, as appropriate, after the Effective Time into which the shares of Common Stock or Preferred Stock, as appropriate, formerly represented by such certificate shall have been reclassified.&#8221;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp; </p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">3.</td>
<td valign="top">The number of shares of the Corporation outstanding and entitled to vote at the time of the adoption of said amendment on September 15, 2016 was 73,038,061.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">4.</td>
<td valign="top">The vote by which the stockholders holding shares in the Corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the Articles of Incorporation, have voted in favor of the amendment is 76%.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">5.</td>
<td valign="top">This Certificate of Amendment will be effective at 12:01 a.m. on June 9, 2017.</td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">This the 7th&nbsp;day of June, 2017.</p></td></tr></tr></tr></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td>&nbsp;</td>
<td colspan="2">
<p style="MARGIN: 0px"><b>CITIUS PHARMACEUTICALS, INC.</b></p></td>
<td></td></tr>
<tr>
<td width="50%">&nbsp;</td>
<td width="3%">&nbsp;</td>
<td width="35%">&nbsp;</td>
<td width="12%">&nbsp;</td></tr>
<tr>
<td></td>
<td>By:</td>
<td style="BORDER-BOTTOM: black 1px solid"><em>/s/ Myron Holubiak</em></td>
<td></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>Myron Holubiak</td>
<td>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>Chief Executive Officer</td>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0">

<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center">2</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p></BODY></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ctxr_ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>

<html><head><title>ctxr_ex991.htm</title><!--Document Created by EDGARMaster--></head><BODY style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 99.1</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size="4">Citius Pharmaceuticals Announces Reverse Stock Split </font></b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><i>Management will seek to secure listing on a senior exchange</i></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in"><b>CRANFORD, N.J., June 8, 2017 </b>&#8211; Citius Pharmaceuticals, Inc. (&#8220;Citius&#8221;) (OTC BB: CTXR), a specialty pharmaceutical company focused on critical care drug products, announced today a reverse stock split of its outstanding common stock at a ratio of 1-for-15 effective at market open on Friday June 9, 2017. The reverse stock split will reduce the number of outstanding shares of the Company's common stock from approximately 75.8 million shares to approximately 5.05 million shares. Upon completion of the split, management will seek to secure listing on a senior exchange. A senior exchange listing would allow us to attract a broader range of investors and to increase share liquidity.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">The reverse stock split will be effective with FINRA (the Financial Industry Regulatory Authority) and in the marketplace at the open of business June 9, 2017, whereupon the stock will begin trading on a split-adjusted basis. The Company's trading symbol on June 9, 2017 will temporarily change to &#8220;CTXRD" and continue for a period of 20 business days from that date, after such time, the symbol will revert to the original symbol of "CTXR".</p>
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">The Company has retained its transfer agent, VStock Transfer LLC, to act as its exchange agent for the reverse stock split. VStock Transfer LLC, will provide stockholders of record as of the effective time with a letter of transmittal providing instructions for the exchange of their stock certificates. Stockholders owning shares via a broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers' particular processes, and will not be required to take any action in connection with the reverse stock split.</p>
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">As a result of the reverse stock split, each 15 shares of common stock held by each stockholder will be converted automatically into one share of common stock, with fractional shares rounded up to the next whole share.&nbsp;No fractional shares will be issued, and no cash or other consideration will be paid. The Company`s stockholders at the 2016 Annual Meeting of Stockholders held on September 9, 2016 authorized the Company&#8217;s Board of Directors to effect a reverse stock split of the Company&#8217;s common stock in a ratio in a range of not less than 1-for-8 and not more than 1-for-20, and the specific ratio of 1-for-15 was subsequently approved by the Company's Board of Directors. </p>
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">Stockholders who are holding their shares in electronic form at their brokerage firms do not have to take any action as the effects of the reverse stock split will automatically be reflected in their brokerage accounts. No further action is required for stockholders holding paper certificates.&nbsp;Certificates representing pre-split holdings will be deemed to represent the stockholder's post-split holdings until the stockholder presents the certificate to the transfer agent, whose contact information appears below.&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">For additional information regarding the reverse stock split, please reference the Company's Definitive Proxy Statement filed with the SEC on August 11, 2016.</p>
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;
<table id="pagebreakd9c6e977-7cce-4aea-a12e-8248e923591d" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">1</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in"><b>About Citius Pharmaceuticals, Inc.</b></p>
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. We focus on developing products that have intellectual property protection and competitive advantages to existing therapeutic approaches. www.citiuspharma.com</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in"><b>Safe Harbor</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to secure listing on a senior exchange; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">For additional information, please contact:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">Andrew Scott
<p style="MARGIN: 0px">Vice President, Corporate Development </p>
<p style="MARGIN: 0px">646-522-8410; ascott@citiuspharma.com</p>
<p style="MARGIN: 0px">
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0">

<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center">2</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p></BODY></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
